ARTICLE | Clinical News

Increlex mecasermin regulatory update

September 5, 2005 7:00 AM UTC

FDA approved an NDA for Increlex mecasermin for the long-term treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone. ...